The Download: “reprogramming” aging, and the hidden sense of interoception

AI's next frontier: longevity. Life Biosciences dosed its first patient in a "reprogramming" trial to reverse aging, targeting age-related diseases. This convergence of biotech and AI-driven cellular analysis could create a $1 trillion market by 2026. Strategic focus: AI’s role in decoding biological reprogramming may unlock longevity therapies, reshaping healthcare economics and life insurance models.